Newly approved by the FDA, Juvederm Volbella is a new hyaluronic acid dermal filler that can provide a smooth and natural improvement in the fullness of ones lips. The studies for Juvederm Volbella have shown this to last for up to 1 year in various patients. Tests have shown that Juvederm Volbella also helped soften the appearance of lines around the mouth, and can be used in the cheek areas too.
While available in Europe prior, the FDA approval now allows it to be available in the United States as of October 2016. Dr. Michele Green is one of the first New York City based cosmetic dermatologists to offer this procedure and can help you enhance your smile naturally without any drastic changes in look and feel. The dermal filler formula includes Vycross2, a filler technology from Allergan that addresses lip fullness, lines around the mouth and potential age related loss in the cheek area. It has been compared to the other popular hyaluronic acid based fillers such as Restylane and Juvederm Voluma. However, Juvederm Volbella has a slightly lower hydrophilic concentration in comparison to Restylane and Juvederm Voluma, and thus absorbs slightly less water from surrounding tissue after the injections. This also means that this new treatment will cause less swelling than previous versions of Juvederm. In addition to that, treatment times are reduced from 45-60 to 35 minutes.
Juvederm Volbella Before & After Photo
*Disclaimer: Results may vary with each patient.
Juvederm Volbella Side Effects
The side effects of Volbella are temporary and include minor swelling, tenderness, bumps, redness and discomfort the first few days after treatment. Injections require only topical anesthesia and can be performed as a “lunch time” procedure. Avoidance of Aspirin, Motrin, Alleve, Coumadin, Vitamin E, Fish oil, or other blood thinners is recommended for ten days before injection to avoid bruising.
Find out more about Juvederm Volbella, contact Dr. Green today via email or at her NYC based office at 212 535 3088
View studies of Juvederm Volbella at – http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496328/